- Home
- INTS vs NYC Comparison
INTS vs NYC Comparison
Compare INTS & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- NYC
- Stock Information
- Founded
- INTS 2012
- NYC 2013
- Country
- INTS United States
- NYC United States
- Employees
- INTS N/A
- NYC N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- NYC Real Estate
- Sector
- INTS Health Care
- NYC Finance
- Exchange
- INTS Nasdaq
- NYC Nasdaq
- Market Cap
- INTS 33.4M
- NYC 27.6M
- IPO Year
- INTS 2023
- NYC N/A
- Fundamental
- Price
- INTS $2.23
- NYC $10.45
- Analyst Decision
- INTS Strong Buy
- NYC
- Analyst Count
- INTS 3
- NYC 0
- Target Price
- INTS $8.50
- NYC N/A
- AVG Volume (30 Days)
- INTS 26.6K
- NYC 8.2K
- Earning Date
- INTS 03-13-2025
- NYC 03-31-2025
- Dividend Yield
- INTS N/A
- NYC N/A
- EPS Growth
- INTS N/A
- NYC N/A
- EPS
- INTS N/A
- NYC N/A
- Revenue
- INTS N/A
- NYC $62,060,000.00
- Revenue This Year
- INTS N/A
- NYC N/A
- Revenue Next Year
- INTS N/A
- NYC $3.18
- P/E Ratio
- INTS N/A
- NYC N/A
- Revenue Growth
- INTS N/A
- NYC N/A
- 52 Week Low
- INTS $1.50
- NYC $5.46
- 52 Week High
- INTS $5.94
- NYC $12.52
- Technical
- Relative Strength Index (RSI)
- INTS 49.26
- NYC 50.89
- Support Level
- INTS $1.84
- NYC $10.50
- Resistance Level
- INTS $2.27
- NYC $12.52
- Average True Range (ATR)
- INTS 0.28
- NYC 0.68
- MACD
- INTS -0.01
- NYC -0.04
- Stochastic Oscillator
- INTS 56.36
- NYC 22.18
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.